Euroimmun
Revvity Q2 Revenues Down on COVID Testing Declines; Organic Dx Revenues Rise
The firm reported 8 percent organic growth in diagnostics, excluding COVID-19, but it also saw lower spending on instruments, contracts, and technology deals.
Climate Change Poses New Challenges for Dx Industry With Potential Emergence of New Diseases
Premium
While many firms have yet to take practical steps dealing with the potential disease implications of climate change, they may soon find they'll have to.
Euroimmun to Distribute GenScript Serology COVID-19 Test in US, Canada
GenScript's test measures a relative concentration of neutralizing antibodies against SARS-CoV-2 in patients and received FDA EUA in late 2020.
PerkinElmer's Euroimmun Gets CE Mark SARS-CoV-2 Antibody Test
The test leverages ELISA technology and uses non-pathogenic viral proteins, enabling its use in common lab settings either manually or automatically.
Euroimmun to Sell Oncgnostics Cervical Cancer Test in Certain Parts of Europe
Oncgnostics also expects the test to be approved by regulators in Canada and to be sold there by the end of the year.